Should I buy or sell Nuvectis Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVCT shares. View NVCT analyst ratings or view top-rated stocks .

What is Nuvectis Pharma's stock price target for 2024?

1 analysts have issued 1 year price targets for Nuvectis Pharma's shares. Their NVCT share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 214.8% from the stock's current price. View analysts price targets for NVCT or view top-rated stocks among Wall Street analysts .

How have NVCT shares performed in 2024?

Nuvectis Pharma's stock was trading at $8.34 on January 1st, 2024. Since then, NVCT stock has decreased by 20.0% and is now trading at $6.67. View the best growth stocks for 2024 here .

When is Nuvectis Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NVCT earnings forecast .

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01.

When did Nuvectis Pharma IPO?

Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.

Who are Nuvectis Pharma's major shareholders?

Nuvectis Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Blue Zone Wealth Advisors LLC (0.08%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur and Shay Shemesh. View institutional ownership trends .

How do I buy shares of Nuvectis Pharma?

Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NVCT

Nuvectis Pharma (NVCT) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free NVCT Stock Alerts

$6.67

-0.05 (-0.74%)

(As of 01:50 PM ET)

Compare

Today's Range: $6.44
▼
$6.78
50-Day Range: $6.41
▼
$11.00
52-Week Range: $6.20
▼
$18.65

Volume: 25,491 shs
Average Volume: 99,344 shs
Market Capitalization: $118.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

Get Nuvectis Pharma alerts:

Nuvectis Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 214.8% Upside
$21.00 Price Target
Short Interest: Bearish
12.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.16
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$51,450 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.52) to ($1.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

419th out of 918 stocks

Pharmaceutical Preparations Industry

185th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Nuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Nuvectis Pharma has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.12% of the float of Nuvectis Pharma has been sold short.
Short Interest Ratio / Days to Cover
Nuvectis Pharma has a short interest ratio ("days to cover") of 7.6.
Change versus previous month
Short interest in Nuvectis Pharma has recently increased by 5.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Nuvectis Pharma does not currently pay a dividend.
Dividend Growth
Nuvectis Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVCT.

3.4

News and Social Media Coverage

News Sentiment
Nuvectis Pharma has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Nuvectis Pharma this week, compared to 1 article on an average week.
Search Interest
4 people have searched for NVCT on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,450.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.52) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvectis Pharma is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvectis Pharma is -4.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvectis Pharma has a P/B Ratio of 9.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Nuvectis Pharma Stock (NASDAQ:NVCT)

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

NVCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NVCT Stock News Headlines

March 20, 2024 | insidertrades.com

Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases 5,000 Shares of Stock

April 17, 2024 | finance.yahoo.com

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

April 19, 2024 | DTI (Ad)

With the “Bitcoin Loophole” you can supercharge the gains by 10x or more

Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…

April 13, 2024 | americanbankingnews.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) to Post Q1 2024 Earnings of ($0.39) Per Share, HC Wainwright Forecasts

April 10, 2024 | americanbankingnews.com

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 1.5%

April 8, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)

April 8, 2024 | finanznachrichten.de

Nuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

April 8, 2024 | markets.businessinsider.com

Nuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick Facts

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

April 8, 2024 | finance.yahoo.com

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

April 8, 2024 | globenewswire.com

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

April 2, 2024 | investorplace.com

5 Healthcare Stocks to Buy for 2024

March 21, 2024 | finance.yahoo.com

Insider Buys Additional US$51k In Nuvectis Pharma Stock

March 19, 2024 | globenewswire.com

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

March 15, 2024 | msn.com

Nuvectis reports initial data from Phase Ib ovarian cancer trial

March 15, 2024 | marketwatch.com

Nuvectis Pharma Shares Rise 11% After Positive Preliminary Data for Cancer Treatment

March 15, 2024 | globenewswire.com

Nuvectis Pharma to Present at the 36th Annual Roth Conference

March 14, 2024 | globenewswire.com

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

March 6, 2024 | investorplace.com

NVCT Stock Earnings: Nuvectis Pharma Misses EPS for Q4 2023

March 5, 2024 | finance.yahoo.com

Nuvectis Pharma Inc (NVCT) Reports Increased Net Loss in FY 2023 Despite Clinical Progress

February 19, 2024 | finance.yahoo.com

Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership

February 9, 2024 | morningstar.com

Nuvectis Pharma Inc NVCT

February 9, 2024 | finance.yahoo.com

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

January 3, 2024 | finance.yahoo.com

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023 | finance.yahoo.com

Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma

November 25, 2023 | finance.yahoo.com

Nuvectis Pharma Insiders Added US$3.75m Of Stock To Their Holdings

November 8, 2023 | msn.com

Nuvectis Pharma GAAP EPS of -$0.37

See More Headlines

Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NVCT
CUSIP: N/A
CIK: 1875558
Web: www.nuvectis.com
Phone: 201-614-3150
Fax: N/A
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.00
High Stock Price Target: $21.00
Low Stock Price Target: $21.00
Potential Upside/Downside: +212.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,260,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -144.80%
Return on Assets: -107.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.75
Quick Ratio: 2.75

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 9.60

Miscellaneous

Outstanding Shares: 17,770,000
Free Float: 10,866,000
Market Cap: $119.41 million
Optionable: Not Optionable
Beta: 0.28

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Ron Bentsur M.B.A. (Age 58)
Co-Founder, Chairman, CEO & President
Comp: $851.61k
Dr. Enrique Poradosu Ph.D. (Age 57)
Co-Founder, Executive VP, Chief Scientific & Business Officer
Comp: $549.07k
Mr. Shay Shemesh (Age 40)
Co-Founder, Executive VP, Chief Development & Operations Officer
Comp: $529.27k
Mr. Michael Carson CPA (Age 47)
Vice President of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nuvectis Pharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVCT shares.
View NVCT analyst ratings or view top-rated stocks.
What is Nuvectis Pharma's stock price target for 2024?: 1 analysts have issued 1 year price targets for Nuvectis Pharma's shares. Their NVCT share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests a possible upside of 214.8% from the stock's current price.
View analysts price targets for NVCT or view top-rated stocks among Wall Street analysts.
How have NVCT shares performed in 2024?: Nuvectis Pharma's stock was trading at $8.34 on January 1st, 2024. Since then, NVCT stock has decreased by 20.0% and is now trading at $6.67.
View the best growth stocks for 2024 here.
When is Nuvectis Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NVCT earnings forecast.

How were Nuvectis Pharma's earnings last quarter?: Nuvectis Pharma, Inc. (NASDAQ:NVCT) issued its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01.
When did Nuvectis Pharma IPO?: Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share.
Who are Nuvectis Pharma's major shareholders?: Nuvectis Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Blue Zone Wealth Advisors LLC (0.08%). Insiders that own company stock include Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur and Shay Shemesh.
View institutional ownership trends.
How do I buy shares of Nuvectis Pharma?: Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NVCT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial